Drugs / DBC-664
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07705035 | Jun 2026 → Apr 2030 expected | endometrium adenocarcinoma, lung adenocarcinoma, malignant germ cell tumor, ovarian adenocarcinoma +1 | Duboce Biopharmaceuticals, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DBC-664 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07705035 ↗ |
| Route | Intravenous | “DBC-664 will be administered intravenously.” NCT07705035 ↗ |